Will PayPal Stock Recover or Keep Sliding?
Payments platform behemoth PayPal Holdings, Inc. (NASDAQ:PYPL) is going through…
Sell
40
ACHV Quote, Financials, Valuation and Earnings
Last price:
$2.54
Seasonality move
:
10.35%
Day range:
$2.28 - $2.50
52-week range:
$1.84 - $5.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.12x
Volume:
214.7K
Avg. volume:
196K
1-year change:
-43.76%
Market cap:
$86M
Revenue:
--
EPS (TTM):
-$1.23
Analysts' Opinion
-
Consensus RatingAchieve Life Sciences has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.00, Achieve Life Sciences has an estimated upside of 545.16% from its current price of $2.48.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $2.48.
Fair Value
-
According to the consensus of 6 analysts, Achieve Life Sciences has 545.16% upside to fair value with a price target of $16.00 per share.
ACHV vs. S&P 500
-
Over the past 5 trading days, Achieve Life Sciences has overperformed the S&P 500 by 14.18% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Achieve Life Sciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Achieve Life Sciences revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Achieve Life Sciences reported revenues of --.
Earnings Growth
-
Achieve Life Sciences earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Achieve Life Sciences reported earnings per share of -$0.36.
Enterprise value:
61.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.07x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$40.8M | -$27.3M | -$39.1M | -$4.4M | -$12.2M | |
| EBITDA | -$40.3M | -$26.7M | -$37.4M | -$4.6M | -$12.1M | |
| Diluted EPS | -$4.06 | -$1.51 | -$1.23 | -$0.24 | -$0.36 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $37M | $44.6M | $27.3M | $17M | $36.5M | |
| Total Assets | $40.3M | $47.5M | $30M | $19.4M | $38.6M | |
| Current Liabilities | $2.9M | $4.6M | $21.6M | $20.8M | $6.7M | |
| Total Liabilities | $3M | $19.5M | $21.7M | $20.8M | $17.7M | |
| Total Equity | $37.3M | $28M | $8.3M | -$1.4M | $20.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$37.6M | -$24.5M | -$29.8M | -$4.4M | -$9.2M | |
| Cash From Investing | -- | -- | -- | -$6K | $11.7M | |
| Cash From Financing | $19.3M | $15.3M | $48.5M | -- | $682K | |
| Free Cash Flow | -$37.6M | -$24.5M | -$29.8M | -$4.4M | -$9.2M | |
ACHV
Sector
Market Cap
$86M
$34.9M
Price % of 52-Week High
44.37%
42.85%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-43.76%
-40.42%
Beta (5-Year)
1.587
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.18
200-day SMA
Sell
Level
$3.96
Bollinger Bands (100)
Sell
Level
2.58 - 3.94
Chaikin Money Flow
Sell
Level
-395.7M
20-day SMA
Buy
Level
$2.38
Relative Strength Index (RSI14)
Buy
Level
51.09
ADX Line
Sell
Level
28.86
Williams %R
Sell
Level
-14.6667
50-day SMA
Sell
Level
$2.77
MACD (12, 26)
Sell
Level
-0.17
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
184.8M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Stock Forecast FAQ
In the current month, ACHV has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ACHV average analyst price target in the past 3 months is $16.00.
-
Where Will Achieve Life Sciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Achieve Life Sciences share price will rise to $16.00 per share over the next 12 months.
-
What Do Analysts Say About Achieve Life Sciences?
Analysts are divided on their view about Achieve Life Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Achieve Life Sciences is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Achieve Life Sciences's Price Target?
The price target for Achieve Life Sciences over the next 1-year time period is forecast to be $16.00 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ACHV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Achieve Life Sciences is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ACHV?
You can purchase shares of Achieve Life Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Achieve Life Sciences shares.
-
What Is The Achieve Life Sciences Share Price Today?
Achieve Life Sciences was last trading at $2.54 per share. This represents the most recent stock quote for Achieve Life Sciences. Yesterday, Achieve Life Sciences closed at $2.48 per share.
-
How To Buy Achieve Life Sciences Stock Online?
In order to purchase Achieve Life Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Eli Lilly Stock Go By 2030?
The weight loss drugs market is heating up quickly and…
Is TSMC the Best Semiconductor Stock to Buy Now?
The new administration has launched a slew of tariffs, paused…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.4T
P/E Ratio: 34x
Alerts
Buy
56
ROOT alert for Apr 23
Root [ROOT] is up 10.62% over the past day.
Buy
72
EFX alert for Apr 23
Equifax [EFX] is up 2.16% over the past day.
Buy
51
CALX alert for Apr 23
Calix [CALX] is down 1.68% over the past day.
